PCRX vs SYK vs ZBH vs MDT

For growth investors, Stryker Corporation (SYK) is the stronger pick with 11.

2% revenue growth year-over-year, versus 3. 6% for Medtronic plc (MDT). Medtronic plc (MDT) offers the better valuation at 21. 6x trailing P/E (14. 1x forward), making it the more compelling value choice. Analysts rate Stryker Corporation (SYK) a "Buy" — based on 50 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Medtronic plc (MDT) is the cheapest at 21.

6x versus Pacira BioSciences, Inc. at 147. 8x. On forward P/E, Pacira BioSciences, Inc. is actually cheaper at 8. 6x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Stryker Corporation wins at 1. 32x versus Medtronic plc's 36. 00x — a reasonable growth-adjusted valuation.

Over the past 5 years, Stryker Corporation (SYK) delivered a total return of +21.

5%, compared to -62. 6% for Pacira BioSciences, Inc. (PCRX). Over 10 years, the gap is even starker: SYK returned +187. 1% versus PCRX's -51. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Medtronic plc (MDT) is the lower-risk stock at 0.

47β versus Zimmer Biomet Holdings, Inc. 's 0. 65β — meaning ZBH is approximately 40% more volatile than MDT relative to the S&P 500. On balance sheet safety, Medtronic plc (MDT) carries a lower debt/equity ratio of 59% versus 66% for Stryker Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Stryker Corporation (SYK) is pulling ahead at 11.

2% versus 3. 6% for Medtronic plc (MDT). On earnings-per-share growth, the picture is similar: Pacira BioSciences, Inc. grew EPS 107. 4% year-over-year, compared to -19. 9% for Zimmer Biomet Holdings, Inc.. Over a 3-year CAGR, SYK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Medtronic plc (MDT) is the more profitable company, earning 13.

9% net margin versus 1. 0% for Pacira BioSciences, Inc. — meaning it keeps 13. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SYK leads at 19. 5% versus 4. 6% for PCRX. At the gross margin level — before operating expenses — PCRX leads at 79. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Stryker Corporation (SYK) is the more undervalued stock at a PEG of 1. 32x versus Medtronic plc's 36. 00x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, Pacira BioSciences, Inc. (PCRX) trades at 8. 6x forward P/E versus 19. 6x for Stryker Corporation — 11. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MDT: 40. 5% to $109. 50.

In this comparison, MDT (3.

6% yield), ZBH (1. 1% yield), SYK (1. 1% yield) pay a dividend. PCRX does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

55), 1. 1% yield, +187. 1% 10Y return). Both have compounded well over 10 years (SYK: +187. 1%, PCRX: -51. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PCRX is a small-cap quality compounder stock; SYK is a mid-cap quality compounder stock; ZBH is a mid-cap quality compounder stock; MDT is a mid-cap income-oriented stock. SYK, ZBH, MDT pay a dividend while PCRX does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.